RPL17 and non-small cell lung carcinoma: Reduced T cell evenness and elevated TCR convergence evaluated by The Oncomine TCRB-SR assay which amplifies the CDR3 region of the TCRB chain were identifying as features of the pretreatment NSCLC tumor microenvironment of responders to anti-PD-1 blockade [72,75].